Review
Medicine, General & Internal
Abdullah Pandor, Jahnavi Daru, Beverley J. Hunt, Gill Rooney, Jean Hamilton, Mark Clowes, Steve Goodacre, Catherine Nelson-Piercy, Sarah Davis
Summary: This study conducted a systematic review to assess the accuracy of risk assessment models (RAMs) in predicting venous thromboembolism (VTE) risk during pregnancy and the early postnatal period. The results suggest that the available data have weak designs and limited generalisability, making the estimates of prognostic accuracy uncertain.
Review
Medicine, General & Internal
Yunqing Xia, Liang Tang, Yu Hu
Summary: This article aims to evaluate the efficacy and safety of novel oral anticoagulants (NOACs) in the treatment of cancer-associated venous thromboembolism through systematic reviews and meta-analyses. Although there is a substantial amount of research supporting the benefits of NOACs in the prevention and treatment of cancer-associated thromboembolism, inconsistent results and questionable data quality have led to controversy, especially in terms of bleeding risk. This study will analyze relevant research through literature search and quality assessment to obtain more accurate conclusions.
Review
Hematology
Dawn Swan, Luke Carter-Brzezinski, Jecko Thachil
Summary: VTE is a common condition with high morbidity and mortality. Athletes have unique risk factors for VTE and may have a higher risk of thrombosis than expected. Anticoagulant treatment can be challenging for athletes who want to return to sports quickly, and those engaging in contact sports may face bleeding complications with extended anticoagulation.
Article
Medicine, General & Internal
Ilia Makedonov, Susan Kahn, Jameel Abdulrehman, Sam Schulman, Aurelien Delluc, Peter L. Gross, Jean-Philippe Galanaud
Summary: Post-thrombotic syndrome (PTS) is a chronic venous insufficiency caused by prior deep venous thrombosis (DVT). Effective preventative measures are needed due to the lack of effective and well-tolerated treatment options for established PTS. Anticoagulation can reduce the risk of PTS, and low-molecular-weight heparin may further reduce the risk through anti-inflammatory properties.
Article
Hematology
Alberto Garcia-Ortega, Raquel Lopez-Reyes, Gabriel Anguera, Grace Oscullo, Agustina Rivas, Luciano Lopez-Jimenez, Alicia Lorenzo, Isabelle Mahe, Maurizio Ciammaichella, Manuel Monreal
Summary: Treatment of venous thromboembolism in solid organ transplant recipients is associated with an increased risk of bleeding compared to non-recipients, mainly influenced by liver transplant recipients. In non-liver solid organ transplant recipients, the risk of bleeding is similar to that in non-recipients.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Nadia Abelhad, Wei Qiao, Naveen Garg, Cristhiam M. Rojas-Hernandez
Summary: This study retrospectively reviewed the treatment of cerebral venous thrombosis in 45 cancer patients, finding recanalization in nearly 60% of cases, a recurrence or propagation rate of 15.6% at 12 months, and major bleeding complications in 15 patients. The findings suggest a narrow therapeutic index of anticoagulation in cancer patients with CVT, highlighting the importance of careful monitoring for anticoagulation effect and bleeding complications. Further larger and controlled studies are needed to validate these observations.
THROMBOSIS JOURNAL
(2021)
Article
Hematology
Annalise M. Martin, Paola Polistena, Asma Mahmud, Brett Bettridge, Alan Morling, Hun Chuah, Agnes S. M. Yong, Michael F. Leahy
Summary: Obesity is a risk factor for VTE, and optimal dosage of enoxaparin in obese patients is still under investigation. A BMI-stratified dosing regimen for enoxaparin therapy proved to be safe and effective in obese patients. Thromboprophylaxis with 40 mg BID enoxaparin was efficacious in preventing VTE without excess bleeding.
THROMBOSIS RESEARCH
(2021)
Review
Oncology
Marta Masini, Matteo Toma, Paolo Spallarossa, Italo Porto, Pietro Ameri
Summary: RCTs have demonstrated that rivaroxaban, edoxaban, and apixaban are equally effective as LMWH in treating CAT, but increase the risk of major gastrointestinal bleeding. Apixaban and rivaroxaban can also prevent CAT in high-risk chemotherapy patients, but may lead to higher bleeding likelihood. Limited data is available for using DOAC in individuals with intracranial tumors or thrombocytopenia, and drug interactions with anticancer agents may affect DOAC effectiveness-safety profile. Current guidelines recommend DOAC as the first-line anticoagulants for CAT, but caution should be exercised in specific patient subgroups.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Clinical Neurology
Anant Naik, Emily Smith, Rajiv Dharnipragada, Joshua S. Catapano, Samuel W. Cramer, Ryan Johnson, Rukhsaar Khanam, Wael Hassaneen, Michael T. Lawton, Paul M. Arnold
Summary: This study conducted a network meta-analysis comparing standard anticoagulation, DOACs, and EVT in the treatment of cerebral venous thrombosis (CVT). The findings showed that DOACs have similar outcomes to standard anticoagulation in the treatment of CVT, while EVT resulted in an increased risk of overall mortality but improved 6-month recanalization rates.
WORLD NEUROSURGERY
(2022)
Article
Clinical Neurology
Anant Naik, Emily Smith, Rajiv Dharnipragada, Joshua S. Catapano, Samuel W. Cramer, Ryan Johnson, Rukhsaar Khanam, Wael Hassaneen, Michael T. Lawton, Paul M. Arnold
Summary: This study compared the effectiveness of standard anticoagulation, DOACs, and EVT in the treatment of CVT, finding that DOACs have similar outcomes as standard anticoagulation, while EVT results in increased overall mortality risk but improved 6-month recanalization rates.
WORLD NEUROSURGERY
(2022)
Article
Medicine, General & Internal
Elena Campello, Paolo Simioni, Paolo Prandoni, Nicola Ferri
Summary: This review summarizes the clinical pharmacology and evidence from phase 2 clinical trials for drugs targeting FXI in the treatment and prevention of thrombosis, showing the potential effectiveness of FXI inhibitors without impairing hemostasis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Letter
Hematology
Elaheh Rahbar, Bryan A. Cotton, Charles E. Wade, Jessica C. Cardenas
Summary: Acquired antithrombin deficiency is a significant risk factor for venous thromboembolism in severely injured patients, and early intervention within the first three days after injury, possibly through antithrombin supplementation, could reduce the risk of VTE and improve patient outcomes.
THROMBOSIS RESEARCH
(2021)
Article
Hematology
Fahrettin Covut, Ramsha Ahmed, Sanchit Chawla, Frank Ricaurte, Christy J. Samaras, Faiz Anwer, Alex V. M. Garcia, Dana E. Angelini, Sandra Mazzoni, Beth Faiman, Jason Valent, Jack Khouri
Summary: The IMPEDE VTE score is a novel risk prediction tool for venous thromboembolism in multiple myeloma patients, with validated predictive ability for VTE occurrence within 6 months. The study found that patients in the low risk group had lower incidence of VTE, while those in the intermediate and high risk groups had higher rates, and a higher ECOG performance status was associated with VTE occurrence. Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not predictors of VTE.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Surgery
Amanda Fazzalari, Giacomo Basadonna, Alper Kucukural, Kahraman Tanriverdi, Milka Koupenova, Natalie Pozzi, Jahnavi Kakuturu, Ann-Kristin U. Friedrich, Ron Korstanje, Nicholas Fowler, Jerrold L. Belant, Dean E. Beyer, Marjory B. Brooks, Eric W. Dickson, Meghan Blackwood, Chris Mueller, J. Alexander Palesty, Jane E. Freedman, Mitchell A. Cahan
Summary: Differences in microRNA expression were observed in the plasma of hibernating black bears, with three microRNAs potentially regulating antithrombin gene expression and contributing to their hemostatic ability during hibernation.
JOURNAL OF SURGICAL RESEARCH
(2021)
Article
Pediatrics
Weiwei Zhu, Hua Zhang, Yan Xing
Summary: This study aimed to analyze the clinical characteristics and risk factors for peripherally inserted central catheter (PICC) placement in premature infants. The results showed a low incidence of PICC-related venous thrombosis, but a high-risk factor was identified in infants whose mothers had autoimmune diseases. For high-risk infants, timely diagnosis and treatment should be provided when limb swelling occurs within one week after catheter placement to reduce adverse events.
